Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.61 |
| ▸ | DRD2 | P14416 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 7/20 | 0.61 |
| ▸ | DRD1 | P21728 | 7/20 | 0.61 |
| ▸ | DRD4 | P21917 | 7/20 | 0.61 |
| ▸ | DRD5 | P21918 | 7/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24685377 | 0.96 | DRD3 (0.62) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL13698247 | 0.91 | DRD2 (0.60) | DRD3DRD2DRD1DRD4DRD5 | |
| SCHEMBL13698240 | 0.85 | SLC6A2 (0.57) | DRD3DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27015512 | 0.80 | DRD2 (0.53) | DRD3DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13974994 | 0.80 | DRD3 (0.61) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL1824340 | 0.79 | SLC6A2 (0.79) | HTR1ASLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13698262 | 0.78 | SLC6A2 (0.57) | DRD2SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2926315 | 0.78 | DRD2 (0.52) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL25946287 | 0.77 | DRD2 (0.69) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL21148627 | 0.76 | DRD3 (0.71) | DRD3DRD2HTR1ADRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD3 32/4885DRD2 35/4885HTR1A 5/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | DRD3 32/4885DRD2 35/4885HTR1A 5/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD3 32/4885DRD2 35/4885HTR1A 5/4885 |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | DRD3 3066/4885DRD2 3505/4885HTR1A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.